Litcius/Paper detail

Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer

Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, Vijayalakshmi Mathrudev, Nandini Menon, Atanu Bhattacharjee, Ajay Singh, Zoya Peelay, Shatabdi Chakraborty, Monica Jadhav, Mitali Alone, Priyanka Bhagyavant, Manali Kolkur, Sujay Srinivas, Sudeep Das, Somnath Roy, Tanmoy Kumar Mandal, Hollis Dsouza, Saswata Saha, Rahul Rai, Anne Srikanth, Darshit Shah, Arif Salam Khan, Hemanth Muthuluri, Amit Kumar, Amit Agarwal, Anu Rajpurohit, Vasu Babu Goli, Anbarasan Sekar, Anoop Mantri, Aditya Pavan Kumar Kanteti, Swaratika Majumdar, Satvik Khaddar, Ramnath Shenoy, Prahlad Elamarthi, Narmadha Rathnasamy, Lakhan Kashyap, George Abraham, Naveen Booma, Vijay Simha, Devendra Chaukar, Prathamesh Pai, Sudhir Nair, Sarbani Ghosh Laskar, Kavita Nawale, Priyanka Naidu, Sushmita Salian, P. D. Shelar, Ravinarayan Raulo, Sachin Dhumal, Kumar Prabhash

2024European Journal of Cancer15 citationsDOI

Topics & Concepts

DocetaxelMedicineClinical endpointAdverse effectHazard ratioInternal medicineChemotherapyRandomized controlled trialOncologyCisplatinCancerSurgeryUrologyConfidence intervalHead and Neck Cancer StudiesOral Health Pathology and TreatmentEsophageal Cancer Research and Treatment
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer | Litcius